Alzamend Neuro (ALZN) to Announce Quarterly Earnings on Tuesday

Alzamend Neuro (NASDAQ:ALZN) will likely be releasing its Q4 2026 results before the market opens on Tuesday, July 28th. Analysts expect Alzamend Neuro to announce earnings of ($0.67) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, July 31, 2026 at 4:00 PM ET.

Alzamend Neuro Stock Performance

Shares of Alzamend Neuro stock opened at $1.26 on Tuesday. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $3.35. The company has a market capitalization of $4.79 million, a P/E ratio of -0.58 and a beta of 0.14. The company has a fifty day moving average of $1.17 and a 200 day moving average of $1.52.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.00.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC grew its stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,506 shares of the company’s stock after acquiring an additional 6,928 shares during the period. Geode Capital Management LLC owned about 0.72% of Alzamend Neuro worth $50,000 at the end of the most recent quarter. Institutional investors and hedge funds own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.